secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0001104659-22-007648
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70
-------------------------------------------------------------------------------

- Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).
- Full-year 2021 adjusted diluted EPS $5.21 (+42.7% YoY); total sales $43.1B (+24.5% reported).
- COVID-19 testing sales $2.3B in Q4, $7.7B full year; company distributed over 1.4 billion tests since pandemic began.
- FY2022 guidance: GAAP EPS at least $3.43, adjusted EPS at least $4.70; COVID testing sales forecast $2.5B.
- Quarterly dividend of $0.47 per share declared, payable Feb. 15, 2022; marks 50 consecutive years of dividend increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465922007648/0001104659-22-007648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465922007648/tm224433d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-007648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer